Seema Khan, MD, on Ductal Carcinoma in Situ: Central MRI and a 12-Gene Expression Assay to Optimize Local Therapy
2023 SABCS
Seema Khan, MD, of Northwestern University and the Robert H. Lurie Comprehensive Cancer Center, discusses the 5-year clinical outcomes of ECOG-ACRIN 4112, a prospective trial that supports the omission of radiotherapy after surgery in patients with ductal carcinoma in situ who have a low DCIS score and its use in patients with intermediate/high DCIS scores (Abstract GS03-01).
The ASCO Post Staff
Eleftherios P. Mamounas, MD, of Orlando Health Cancer Institute, discusses primary outcomes from the NRG Oncology/NSABP B-51/RTOG 1304 study of locoregional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy (Abstract GS02-07).
The ASCO Post Staff
Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses data from the phase II KEYLYNK-009 study, which compared pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (Abstract GS01-05).
The ASCO Post Staff
Sara A. Hurvitz, MD, of Fred Hutchinson Cancer Research Center, University of Washington, discusses phase III findings of the HER2CLIMB-02 study, which showed the combination of tucatinib and trastuzumab emtansine improved progression-free survival in patients with previously treated, HER2-positive, locally advanced or metastatic breast cancer (including those with brain metastases) (Abstract GS01-10).
Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses updated phase III results from the TROPION-Breast01 study. The data showed an improvement in progression-free survival with datopotamab deruxtecan compared with investigator’s choice of chemotherapy across all subgroups of patients with inoperable or metastatic hormone receptor–positive, HER2-negative breast cancer who have received one to two prior lines of chemotherapy (Abstract GS02-01).
The ASCO Post Staff
Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses phase III findings from the KEYNOTE-756 study, which showed that adding pembrolizumab to chemotherapy increases the pathologic complete response rate and lowers the residual cancer burden in patients with early-stage, high-risk ER-positive or HER2-negative breast cancer (Abstract GS01-02).
